✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Rybelsus

Released: Last reviewed:

Brand name for oral semaglutide, FDA-approved for type 2 diabetes mellitus. Daily tablet (3, 7, 14 mg).

By Novo Nordisk
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Rybelsus overview

Brand name for oral semaglutide, FDA-approved for type 2 diabetes mellitus. Daily tablet (3, 7, 14 mg).

Rybelsus at a glance

Manufacturer
Novo Nordisk
FDA status
FDA-approved

Related pages

Key facts, checked November 20, 2026

Rybelsus is once-daily oral semaglutide for type 2 diabetes. The shared Rybelsus and Ozempic tablets label (effective January 30, 2026) covers blood-sugar control in adults with type 2 diabetes and lowering the risk of major cardiovascular events in adults with type 2 diabetes at high risk. FDA’s shortage data mark the original Rybelsus 3, 7 and 14 mg tablets as “to be discontinued” (June 4, 2026 posting). The CMS fact sheet on 2027 negotiated prices lists a $274 Medicare price for a 30-day supply of Rybelsus from January 1, 2027. The Wegovy pill, a different oral semaglutide product, is the one approved for weight management in adults.